Different Doses of Nebulized Magnesium Sulphate in Status Asthmaticus

Ziauddin University126 enrolled

Overview

In this study investigators will use magnesium sulphate in the nebulized form in children between 2 and 12 years of age as an acute reliever for acute severe asthma. Aim of this study is to determine that whether adding low (250mg), intermediate (500mg), and high doses (750mg) of magnesium sulphate in the 1st hour of treatment has any difference in the improvement of clinical condition of the patient and length of hospital stay. There will be total 108 patients having 2 groups. 1st group will receive only Ventolin while 2nd group will be given Ventolin and Magnesium sulphate.

This randomized clinical trial will include 126 patients after taking informed consent who will meet the eligibility criteria. Patients will be randomly distributed in 2 groups on alternate basis as computerized generated number. Improvement will be assessed in terms of clinical condition i.e., Heart Rate, Respiratory Rate, blood pressure, pattern of breathing oxygen saturation and Pediatric Respiratory Assessment Measure (PRAM) score at start of treatment and then afterwards at 20 min interval up to 1 hour and then at 2nd hour and then after every 6 hours for 24 hours.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

126

Conditions

Status Asthmaticus

Interventions

Magnesium Sulfate 500 mg/ml+ ventolinDRUG

3 doses of magnesium sulphate i.e; 250mg(0.5ml), 500mg(1ml), 750mg(1.5ml) will be used in nebulized form

VentolinDRUG

it will be given to control group in nebulized form after every 20 min in 1st hour

Eligibility

Sex: ALLMin age: 2 YearsMax age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Children between 2 to 12 years of age. 2. Children with the diagnosis of asthma having a pram score of more than 4. 3. Children with reactive airways Exclusion Criteria: 1. Critically ill children who require intubation or mechanical ventilation. 2. Having hypersensitivity or allergy to MgSO4. 3. with history of chronic lung impairment. 4. Whose parents are not giving informed consent for participation in research.

Locations (1)

Rabia Asif

Karachi, Sindh, Pakistan

Outcomes

Primary Outcomes

Change in Pediatric Respiratory Assessment Measure (PRAM) score from the baseline

The outcome measure was the response to treatment in terms of change in Pediatric Respiratory Assessment Measure (PRAM) score from the baseline, i.e; suprasternal indrawing, scalene retractions, wheezing, air entry, oxygen saturation on room air. Change in PRAM score means decrease in score i.e; mild (0-4), moderate (5-8), severe(9-12), impending respiratory failure (12+).